Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions

Alexander Liu,Raheel Ahmed,Mansimran Singh Dulay,Joseph Okafor,Alessia Azzu,Kamleshun Ramphul,Rui Shi,Gerald Ballo,John Arun Baksi,Kshama Wechalekar,Rajdeep Khattar,Peter Collins,Athol Umfrey Wells,Vasilis Kouranos,Rakesh Sharma
DOI: https://doi.org/10.1002/ehf2.15113
2024-10-19
ESC Heart Failure
Abstract:Outcomes of cardiac resynchronization therapy in cardiac sarcoidosis patients with a range of left ventricular ejection fractions. Aims In cardiac sarcoidosis (CS) patients, the benefit of cardiac resynchronization therapy (CRT) remains unclear. We sought to assess the short‐term and long‐term effects of CRT in CS patients with a range of left ventricular (LV) ejection fractions (LVEFs). Methods Consecutive CS patients with heart failure with reduced ejection fraction (HFrEF; LVEF ≤ 40%), mildly reduced ejection fraction (HFmrEF; LVEF 41%–49%) and preserved ejection fraction (HFpEF; LVEF ≥ 50) treated with CRT under the care of a tertiary UK centre between 2008 and 2023 were reviewed. CRT response was defined by >5% improvement in serial LVEF. The primary endpoint was a composite of all‐cause mortality, cardiac transplantation or unplanned hospitalization for decompensated heart failure. The secondary endpoint included ventricular arrhythmic events. Results Of the 100 patients enrolled (age 58 ± 10 years; 71% male), 63 had HFrEF, 17 had HFmrEF and 20 had HFpEF. After short‐term follow‐up (9.8 ± 5.4 months), HFrEF patients demonstrated significant LVEF response (P
cardiac & cardiovascular systems
What problem does this paper attempt to address?